Zoetis Q4 2020 Earnings Report
Key Takeaways
Zoetis reported strong Q4 2020 results, with revenue increasing by 8% to $1.8 billion and net income reaching $359 million. The company's companion animal products, particularly Simparica Trio and key dermatology brands, drove growth in the U.S. International sales also increased, with companion animal products and swine products in China contributing to the positive results. Looking ahead, Zoetis provided full year 2021 revenue guidance of $7.400 - $7.550 Billion, with Diluted EPS of $4.02 - $4.14 on a Reported Basis, or $4.36 - $4.46 on an Adjusted Basis.
Revenue for Q4 2020 reached $1.8 billion, an 8% increase compared to Q4 2019.
Net income for Q4 2020 was $359 million, or $0.75 per diluted share.
U.S. revenue increased by 11%, driven by companion animal products.
International revenue increased by 5% on a reported basis and 7% operationally.
Zoetis
Zoetis
Zoetis Revenue by Segment
Zoetis Revenue by Geographic Location
Forward Guidance
Zoetis is providing full year 2021 guidance, which includes: •Revenue between $7.400 billion to $7.550 billion •Reported diluted EPS between $4.02 to $4.14 •Adjusted diluted EPS between $4.36 to $4.46
Revenue & Expenses
Visualization of income flow from segment revenue to net income